An active comparator, parallel group study comparing levofloxacin 1.5% and moxifloxacin 0.5% in patients undergoing cataract surgery showed significantly greater aqueous penetration of levofloxacin, measured as area under the curve over a 6-hour interval. Levofloxacin also had a significantly higher Cmax and significantly higher maximum concentration at the end of the dose interval. These findings indicate a possible role for levofloxacin in the prophylaxis of endophthalmitis at the time of cataract surgery.
Gatifloxacin is shown to rapidly eradicate methicillin-resistant Staphylococcus aureus clinical isolates, according to study
A study evaluating eradication of methicillin-resistant Staphylococcus aureus (MRSA) by fluoroquinolones shows that the commercially available preparation of gatifloxacin 0.3% (Zymar, Allergan) has superior bactericidal activity compared with the commercially available preparation of moxifloxacin 0.5% (Vigamox, Alcon). Gatifloxacin was more active than moxifloxacin alone, and its activity was enhanced by the presence of the preservative benzalkonium chloride.
Loteprednol etabonate 0.5%/tobramycin 0.3% ([LE/T]; Zylet, Bausch & Lomb) was found to be superior to dexamethasone 0.1%/tobramycin 0.3% ([DM/T]; Tobradex, Alcon Laboratories) in a comparison study that tested ocular comfort and tolerability in healthy volunteers. LE/T also has shown to be less likely to cause increases in IOP levels compared with DM/T. LE/T may provide some small advantages, possibly resulting from formulation differences and/or the steroid used, the researchers concluded.
Besifloxacin (Optura, Bausch & Lomb) was found to be more effective than gatifloxacin and moxifloxacin in reducing the number of methicillin-resistant Staphylococcus aureus organisms in the cornea when applied topically 10 to 18 hours after infection.
Difluprednate ophthalmic emulsion 0.05% (Durezol, Sirion Therapeutics) was at least as effective as prednisolone acetate suspension 1% (Pred Forte, Allergan), dosed twice as often, in the treatment of endogenous anterior uveitis. Equivalent effectiveness with less-frequent dosing could improve patient compliance, according to one ophthalmologist.
A prospective, randomized, investigator-masked study was conducted to compare twice-daily and four-times-daily dosing of a corticosteroid after cataract surgery. All patients also received bromfenac 0.09% (Xibrom, Ista Pharmaceuticals). No significant differences in macular thickening or anterior chamber cell and flare were observed between groups.
Ecabet sodium (ISTA Pharmaceuticals), an anti-ulcer and gastritis drug under development for the treatment of dry eye, showed positive results in a phase IIb clinical trial of the drug.
Bepotastine besilate 1.0% (Bepreve, ISTA Pharmaceuticals), an ocular allergy compound under new drug application review by the FDA, is effective in reducing ocular itching associated with allergic conjunctivitis and also seems to improve other allergy symptoms.
To help combat the unfavorable view the public has about pharmaceutical companies, the Pharmaceutical Research and Manufacturers of America (PhRMA) recently published updates to their "Code on Interactions with Health-care Professionals," which went into effect Jan. 1. PhRMA's basis for the updates is that "interactions should be focused on informing health-care professionals about products, providing scientific and educational information, and supporting medical education." Changes have been made in three major categories: gifting, consulting, and enforcement of the code.
The FDA has accepted for review a new drug application filed by Sirion Therapeutics Inc. for ganciclovir ophthalmic gel 0.15%.